Durvalumab [DUR7]

Durvalumab monotherapy for patients with limited- stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiotherapy where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anti-cancer therapy with durvalumab monotherapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
2. The patient has a histologically or cytologically determined diagnosis of small cell lung cancer (SCLC).
3. The patient has limited stage SCLC.
4. The patient has been treated with platinum-based chemoradiotherapy (etoposide plus either cisplatin or carboplatin) and there has been no evidence of disease progression following this. Please mark below whether the radiotherapy was concurrent with chemotherapy or sequential after chemotherapy:

• concurrent radiotherapy and chemotherapy or
• sequential radiotherapy after chemotherapy

Note

Note: NHS England expects concurrent chemoradiotherapy to be the preferred way of giving platinum-based chemotherapy and radiotherapy in line with the 2019 NICE Clinical Guideline for SCLC.

5. The patient has been treated with prophylactic cranial irradiation (PCI) or not:

• yes, the patient has received PCI or
• no, the patient has not been treated with PCI

6. Treatment with durvalumab maintenance monotherapy will continue until disease progression or symptomatic deterioration or unacceptable toxicity or withdrawal of patient consent or for a maximum of 2 calendar years, whichever occurs first. 7.The patient will start his/her first treatment with durvalumab within 42 days of the last active treatment date of the concurrent chemoradiotherapy treatment program (in most cases this will be 42 days from the final dose of systemic chemotherapy)
7. The patient has a current ECOG performance status of 0 or 1.
8. The patient has no symptomatically active brain metastases or leptomeningeal metastases.
9. The patient has had no prior treatment with anti-PD-L1/PD-1 therapy for small cell lung cancer, unless this was received for this indication via a company early access program and all treatment criteria on this form are fulfilled.
10. When a treatment break of more than 12 weeks beyond the expected 4-weekly cycle length is needed, I will complete a treatment break approval form to restart treatment. This must be approved before durvalumab is re-commenced
11. Durvalumab will be otherwise used as set out in its Summary of Product Characteristics (SPC).

CDF funded From: 16 September 2025

Additional information

Form version: -

CDF Managed Access: No

NICE Technology Appraisal: NA (NA)

Current Form Version

Note

The data on this page was produced using version 1.374 of the CDF list, downloaded from NHS England’s website on 19 September 2025 at 18:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.